Brucellosis Vaccines Market Size to Attain USD 389.50 Mn by 2033

The global brucellosis vaccines market size was estimated at USD 242.70 million in 2023, growing at a CAGR of 4.84% from 2024 to 2033. Brucellosis is a zoonotic disease that affects both animals and humans, primarily caused by bacteria of the genus Brucella. The Brucellosis Vaccines Market is focused on the production and distribution of vaccines for preventing this disease in livestock, such as cattle, sheep, and goats. Vaccination plays a crucial role in controlling the spread of brucellosis, thus protecting animal health and reducing the risk of transmission to humans. This market encompasses various types of vaccines, including live attenuated and inactivated vaccines, tailored for different species and strains of Brucella.

Brucellosis Vaccines Market Size 2024 to 2033

Key Points

The North America brucellosis vaccines market size reached USD 104.36 million in 2023 and is expected to surpass around USD 167.49 million by 2033.
North America has dominated the market with revenue share of 43% in 2023.
By application, in 2023, the cattle segment has accounted 57% revenue share in 2023.
By type, the RB51 vaccine segment dominated the market with revenue share of 43% in 2023.
By Vaccine Type, the DNA Vaccines segment has captured 32.5% revenue share in 2023.
By distribution channel, the public segment had the largest market share in 2023.

Growth Factors:

The growth of the Brucellosis Vaccines Market is driven by several factors. Increasing awareness of the zoonotic nature of brucellosis and its impact on human health is one key driver, prompting a greater demand for effective vaccination programs. Additionally, the expansion of the livestock industry, especially in developing regions, leads to increased demand for animal health products, including vaccines. Government initiatives and funding for controlling zoonotic diseases also play a significant role in market growth.

Get a Sample: https://www.precedenceresearch.com/sample/4113

Region Insights:

Different regions experience varying levels of impact from brucellosis, which influences the market for vaccines. In regions where the disease is more prevalent, such as parts of Africa, Asia, and Latin America, the demand for brucellosis vaccines is high due to the need for disease control in livestock. In contrast, developed regions like North America and Europe have more established vaccination programs and regulatory frameworks, but still contribute to market growth through research and development of new vaccine options.

Brucellosis Vaccines Market Scope

Report Coverage	Details
Global Market Size in 2023	USD 242.70 Million
Global Market Size in 2024	USD 254.46 Million
Global Market Size by 2033	USD 389.50 Million
Growth Rate from 2024 to 2033	CAGR of 4.84%
Largest Market	North America
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	By Type, By Vaccine, By Application, and By Distribution Channel
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Brucellosis Vaccines Market Dynamics

Drivers:

Key drivers for the Brucellosis Vaccines Market include the increasing prevalence of the disease in certain regions, the need for improved livestock health, and the demand for high-quality animal products. Public health campaigns and regulatory support for controlling zoonotic diseases also boost the market. Advances in vaccine technology and production methods, as well as rising investment in animal health, further drive market growth.

Opportunities:

Opportunities in the Brucellosis Vaccines Market arise from the development of more effective and safer vaccines. Research into new vaccine types, including recombinant vaccines and DNA-based vaccines, presents potential for improved efficacy. There is also scope for expansion in untapped markets where vaccination programs are not yet widespread. Partnerships and collaborations between vaccine manufacturers and governments or non-profit organizations can further enhance market opportunities.

Challenges:

The market faces challenges such as the complexity of brucellosis as a disease and the need for vaccines that are safe and effective across different species. Regulatory hurdles and the high cost of vaccine development can also pose challenges. Additionally, achieving high vaccination coverage in rural and underserved areas may be difficult due to logistical and financial constraints. These challenges necessitate ongoing research and strategic planning to ensure the market’s growth and success.

Brucellosis Vaccines Market Recent Developments

In March 2024, Boehringer Ingelheim, a renowned player in the animal health sector, collaborated with Square Pharmaceuticals to launch Aftovaxpur in Bangladesh. This advanced foot-and-mouth disease (FMD) vaccine is specifically formulated for ruminants, including cattle and sheep, aiming to enhance livestock health in the region.
In October 2023, Zoetis, a leading animal health company based in the US, made headlines by acquiring Semex, a Canadian company specializing in bovine genetics and reproductive technology. This strategic move aims to bolster Zoetis’ standing in the cattle health market, particularly by enhancing its brucellosis vaccine offerings. The acquisition brings valuable expertise and a robust distribution network from Semex, strengthening Zoetis’ position in cattle breeding management.
In April 2023, Cornell University College of Veterinary Medicine (CVM) scientists researched and developed a novel diagnostic test to identify Brucella canis. This test helps in the early diagnosis of this zoonotic disease, which can spread to humans through contact with infected dogs. This will boost vaccination over time.
In July 2023, A notable development came from Hester Biosciences, an animal health company in India, with the launch of a new oral brucellosis vaccine for cattle. This innovative vaccine, based on the Brucella Abortus B19 strain, offers a more convenient and potentially cost-effective alternative to traditional injection-based vaccines. The introduction of this oral vaccine could open up new market segments, particularly in regions with limited resources, such as India.